Inventor · disambiguated record
Robert G. K. Donald
Also filed as: DONALD ROBERT · DONALD ROBERT G K
25 granted patents·9 pending applications·190 citations·filing 2000–2024
96Inventor score
Top patents by PatentIndex Score
34 records- 0197US9187536B1Compositions relating to a mutant Clostridium difficile toxin and methods thereofWYETH LLC·Filed 2015·Granted Nov 17, 2015·19 cites·20 claims
- 0296US10982198B2Compositions and methods relating to a mutant Clostridium difficile toxinPFIZER·Filed 2018·Granted Apr 20, 2021·4 cites·17 claims
- 0396US10774117B2Compositions relating to a mutant clostridium difficile toxin and methods thereofWYETH LLC·Filed 2017·Granted Sep 15, 2020·6 cites·31 claims
- 0496US8557548B2Compositions relating to a mutant Clostridium difficile toxin and methods thereofWYETH LLC·Filed 2013·Granted Oct 15, 2013·25 cites·21 claims
- 0595US11208633B2Compositions and methods relating to a mutant Clostridium difficile toxinPFIZER·Filed 2019·Granted Dec 28, 2021·3 cites·15 claims
- 0695US10226525B2Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereofPFIZER·Filed 2016·Granted Mar 12, 2019·18 cites·32 claims
- 0795US9745354B2Compositions relating to a mutant Clostridium difficile toxin and methods thereofWYETH LLC·Filed 2014·Granted Aug 29, 2017·15 cites·28 claims
- 0895USRE46518ECompositions relating to a mutant Clostridium difficile toxin and methods thereofWYETH LLC·Filed 2016·Granted Aug 22, 2017·9 cites·48 claims
- 0995US8900597B2Compositions relating to a mutant Clostridium difficile toxin and methods thereofWYETH LLC·Filed 2013·Granted Dec 2, 2014·15 cites·41 claims
- 1095US8481692B2Compositions relating to a mutant Clostridium difficile toxin and methods thereofSIDHU MANINDER K·Filed 2012·Granted Jul 9, 2013·30 cites·20 claims
- 1194USRE48862ECompositions relating to a mutant Clostridium difficile toxin and methods thereofWYETH LLC·Filed 2019·Granted Dec 28, 2021·3 cites·20 claims
- 1294US10597428B2Compositions relating to a mutant clostridium difficile toxin and methods thereofWYETH LLC·Filed 2019·Granted Mar 24, 2020·7 cites·20 claims
- 1394USRE46376ECompositions relating to a mutant Clostridium difficile toxin and methods thereofWYETH LLC·Filed 2015·Granted Apr 25, 2017·9 cites·21 claims
- 1493USRE48863ECompositions relating to a mutant Clostridium difficile toxin and methods thereofWYETH LLC·Filed 2019·Granted Dec 28, 2021·3 cites·20 claims
- 1592US10946086B2Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereofPFIZER·Filed 2019·Granted Mar 16, 2021·5 cites·7 claims
- 1692US10787652B2Compositions and methods relating to a mutant clostridium difficile toxinPFIZER·Filed 2013·Granted Sep 29, 2020·6 cites·17 claims
- 1791US11535652B2Compositions relating to a mutant clostridium difficile toxin and methods thereofWYETH LLC·Filed 2019·Granted Dec 27, 2022·2 cites·19 claims
- 1888US2025002875A1Compositions and methods relating to a mutant clostridium difficile toxinPFIZER·Filed 2024·Application pending·0 cites
- 1987US2023391835A1Compositions relating to a mutant clostridium difficile toxin and methods thereofWYETH LLC·Filed 2022·Application pending·0 cites
- 2085US11260119B2Escherichia coli compositions and methods thereofPFIZER·Filed 2019·Granted Mar 1, 2022·3 cites·25 claims
- 2180US6555358B1Polynucleotide encoding eimeria tenella cGMP dependent protein kinaseMERCK & CO INC·Filed 2000·Granted Apr 29, 2003·6 cites·9 claims
- 2279US2023346903A1Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereofPFIZER·Filed 2022·Application pending·0 cites
- 2377US12458689B2Escherichia coli compositions and methods thereofPFIZER·Filed 2024·Granted Nov 4, 2025·0 cites·14 claims
- 2476US2025121044A1Escherichia coli compositions and methods thereofPFIZER·Filed 2024·Application pending·0 cites
- 2575US11952597B2Compositions and methods relating to a mutant Clostridium difficile toxinPFIZER·Filed 2020·Granted Apr 9, 2024·0 cites·5 claims
- 2674US7125700B2Cyclic GMP dependent protein kinase as a chemotherapeutic target for antiprotozoal agentsMERCK & CO INC·Filed 2003·Granted Oct 24, 2006·2 cites·1 claims
- 2771US2021145957A1Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereofPFIZER·Filed 2021·Application pending·0 cites
- 2870US2024216495A1Compositions and methods for eliciting an immune response against clostridium difficilePFIZER·Filed 2023·Application pending·0 cites
- 2969US12128095B2Escherichia coli compositions and methods thereofPFIZER·Filed 2022·Granted Oct 29, 2024·0 cites·29 claims
- 3059US2021268095A1Escherichia coli compositions and methods thereofPFIZER·Filed 2021·Application pending·0 cites
- 3157US2020254081A1Compositions and methods for eliciting an immune response against clostridium difficilePFIZER·Filed 2018·Application pending·0 cites
- 3255US7718390B2Toxoplasma gondii cylclic GMP dependent protein kinase G as a chemotherapeutic target for antiprotozoal agentsMERIAL LTD·Filed 2006·Granted May 18, 2010·0 cites·4 claims
- 3351US2023000966A1Escherichia coli compositions and methods thereofPFIZER·Filed 2020·Application pending·0 cites
- 3442US7671181B2Polynucleotides encoding coccidian parasite casein kinase I, a chemotherapeutic target for antiprotozoal agentsMERCK SHARP & DOHME·Filed 2005·Granted Mar 2, 2010·0 cites·9 claims
Join the waitlist — get patent alerts
Get an alert when Robert G. K. Donald files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →